Patrick Borgen, MD, built Brooklyn's breast cancer program from 47 patients to 8,000. Now he and Joshua Feinberg, MD discuss what surgery looks like next.
Patrick Borgen, MD
Advertisement
Articles by Patrick Borgen, MD
Patrick Borgen, MD, says this is due to earlier diagnoses, better class prediction through genomic profiling and characteristics of the disease, as well as targeted therapies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
3
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
4
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
5